Alps Advisors Inc. Has $410,000 Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Alps Advisors Inc. reduced its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 16.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,720 shares of the medical instruments supplier’s stock after selling 4,129 shares during the quarter. Alps Advisors Inc.’s holdings in OraSure Technologies were worth $410,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Legal & General Group Plc raised its holdings in shares of OraSure Technologies by 3.0% during the first quarter. Legal & General Group Plc now owns 113,160 shares of the medical instruments supplier’s stock worth $1,907,000 after acquiring an additional 3,291 shares in the last quarter. Rhumbline Advisers raised its holdings in OraSure Technologies by 2.8% during the first quarter. Rhumbline Advisers now owns 135,581 shares of the medical instruments supplier’s stock valued at $2,290,000 after buying an additional 3,678 shares in the last quarter. Northern Trust Corp raised its holdings in OraSure Technologies by 0.6% during the first quarter. Northern Trust Corp now owns 757,400 shares of the medical instruments supplier’s stock valued at $12,792,000 after buying an additional 4,514 shares in the last quarter. McCollum Christoferson Group LLC raised its holdings in OraSure Technologies by 4.7% during the second quarter. McCollum Christoferson Group LLC now owns 115,089 shares of the medical instruments supplier’s stock valued at $1,896,000 after buying an additional 5,135 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in OraSure Technologies during the first quarter valued at about $113,000. 92.25% of the stock is owned by hedge funds and other institutional investors.

In other OraSure Technologies news, Director Charles W. Patrick sold 8,000 shares of OraSure Technologies stock in a transaction on Monday, August 27th. The shares were sold at an average price of $16.29, for a total transaction of $130,320.00. Following the completion of the sale, the director now owns 54,298 shares of the company’s stock, valued at approximately $884,514.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.90% of the stock is currently owned by insiders.

Several equities analysts have weighed in on OSUR shares. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. TheStreet raised OraSure Technologies from a “c+” rating to a “b” rating in a research report on Thursday, August 9th. Stephens downgraded OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research report on Monday, July 16th. Finally, BidaskClub downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $21.33.

Shares of NASDAQ:OSUR traded down $0.02 during trading on Friday, reaching $16.01. The stock had a trading volume of 354,100 shares, compared to its average volume of 541,917. OraSure Technologies, Inc. has a 52 week low of $12.86 and a 52 week high of $23.01. The stock has a market capitalization of $994.07 million, a P/E ratio of 31.57, a price-to-earnings-growth ratio of 4.00 and a beta of 1.56.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The firm had revenue of $43.60 million during the quarter, compared to analyst estimates of $42.24 million. During the same quarter in the previous year, the business earned $0.09 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. analysts anticipate that OraSure Technologies, Inc. will post 0.33 earnings per share for the current fiscal year.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Further Reading: How Do I Invest in Dividend Stocks

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply